Abstract
The Consortium of Eosinophilic Gastrointestinal Diseases and The International Gastrointestinal Eosinophil Researchers organized a day-long symposium at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology. The symposium featured a review of recent discoveries in the basic biology and pathogenesis of eosinophilic gastrointestinal diseases (EGIDs) in addition to advances in our understanding of the clinical features of EGIDs. Diagnostic and management approaches were reviewed and debated, and clinical trials of emerging therapies were highlighted. Herein, we briefly summarize the breakthrough discoveries in EGIDs.
Original language | English (US) |
---|---|
Pages (from-to) | 1382-1393 |
Number of pages | 12 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 152 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2023 |
Funding
We also thank the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) (U54AI117804), which is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and funded through collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy groups including American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Diseases (CURED), and Eosinophilic Family Coalition (EFC). As a member of the RDCRN, CEGIR is also supported by its Data Management and Coordinating Center (DMCC) (U2CTR002818). Funding support for the DMCC is provided by the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Neurological Disorders and Stroke (NINDS).
Keywords
- Eosinophilic esophagitis
- eosinophil
- eosinophilic gastritis
- food allergy
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology